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A B S T R A C T
Endothelial cells line blood vessels and provide a dynamic interface between the blood and tissues. They
remodel to allow leukocytes, ﬂuid and small molecules to enter tissues during inﬂammation and infections.
Here we compare the signaling networks that contribute to endothelial permeability and leukocyte transen-
dothelial migration, focusing particularly on signals mediated by small GTPases that regulate cell adhesion and
the actin cytoskeleton. Rho and Rap GTPase signaling is important for both processes, but they diﬀer in that
signals are activated locally under leukocytes, whereas endothelial permeability is a wider event that aﬀects the
whole cell. Some molecules play a unique role in one of the two processes, and could therefore be targeted to
selectively alter either endothelial permeability or leukocyte transendothelial migration.
1. Introduction
Endothelial cells (ECs) form a semi-permeable barrier to separate
the blood stream from the underlying organs and tissues and control
the transport of ﬂuids, solutes and cells across blood vessel walls. The
barrier is mediated by endothelial cell-cell adhesions including tight
junctions (TJ), adherens junctions (AJ) and a variety of other adhesion
molecules including PECAM-1 and nectins, which are connected to the
actin cytoskeleton via diﬀerent adaptor molecules (Fig. 1). The
architecture and the composition of cell-cell junctions varies between
vascular beds depending on the organ-speciﬁc requirements [1,2]. In
addition to maintaining adhesion between ECs, cell-cell junctions
control vascular permeability and leukocyte migration via a complex
balance between multiple signaling molecules (Figs. 1 and 2) [3,4].
TJs regulate the diﬀusion of ions and polar solutes and block
penetration of large macromolecules across ECs. TJs are formed by the
homophilic cell-cell adhesion molecules occludin, claudins and junc-
tional adhesion molecules (JAMs) (Fig. 1) [5,6]. Claudins are the
principal barrier-forming proteins, in particular claudin-5 is critical for
endothelial permeability in vivo and in vitro [7]. Occludin and claudins
are linked to zonula occludens (ZO)-1, ZO-2, ZO-3, cingulin and other
protein complexes, which mediate the interaction between the adhe-
sion molecules and actin ﬁlaments [5]. The JAM family is composed of
three closely related proteins JAM-A, -B and -C, and by the coxsackie
and adenovirus receptor (CAR). The JAMs mediate endothelial cell-cell
interaction and regulate leukocyte transendothelial migration (TEM)
[8]. Both JAMs and CAR regulate permeability by supporting TJ
function and assembly [9].
VE-cadherin is the key transmembrane component of endothelial
AJs and is expressed only in ECs [10]. VE-cadherin together with
PECAM-1 initiates and maintains endothelial cell-cell contact, holding
the ECs together to give mechanical support to the endothelium and
provide endothelial junction stability [11,12]. AJs can regulate expres-
sion of TJ components and TJ organization follows AJ formation
[11,13]. In addition, AJs and TJs are interconnected [14], for example
ZO proteins crosstalk with AJs [15]. VE-cadherin is linked indirectly
via its cytoplasmic tail to actin ﬁlaments by a complex of proteins
including α- and β-catenins, plakoglobin (γ-catenin), p120-catenin,
vinculin and α-actinin (Fig. 1) [16], which are vital for junctional
stability and also for the dynamic opening and closing of junctions [17].
Here we discuss the roles of endothelial cell-cell junctions in
signaling leading to changes to endothelial permeability and during
leukocyte transendothelial migration (TEM), with a particular focus on
small GTPases.
2. Regulation of small GTPases
Several members of the Ras superfamily of small GTPases con-
tribute to endothelial cell-cell adhesion and hence regulate endothelial
permeability and/or leukocyte TEM. These include Rap1, Rap2 and
several Rho family GTPases (Figs. 2 and 3). Most small GTPases cycle
between an inactive GDP-bound conformation and an active GTP-
bound conformation. This cycling is regulated by guanine nucleotide
exchange factors (GEFs), which catalyse the exchange of GDP for GTP,
thereby activating the proteins, and by GTPase-activating proteins
(GAPs), which stimulate GTP hydrolysis and inactivate the proteins.
The interaction between small GTPases and their downstream eﬀectors
often requires their localisation to membranes, which is mediated by
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post-translational modiﬁcation by lipids (prenylation and/or palmitoy-
lation) [18,19]. For example, geranylgeranylation of Rho GTPases is
required for thrombin-induced permeability in ECs [20]. Some small
GTPases are inhibited by binding to proteins that extract them from
membranes, including guanine nucleotide dissociation inhibitors
(GDIs) and 14-3-3 proteins [21,22]. Small GTPases are rapidly
activated by cell-surface receptors, and a single GTPase can interact
with multiple downstream targets to induce a range of cellular
responses in a spatio-temporal fashion, depending on the stimulus
and cell type [19].
3. Signaling to endothelial junctions in vascular permeability
Endothelial cell-cell junctions remodel dynamically in response to
multiple extracellular stimuli, which transiently increase or decrease
endothelial permeability and thereby regulate the entry of polar solutes
and macromolecules into the tissues from the blood stream (Fig. 2) [4].
For example, pro-inﬂammatory stimuli such as thrombin, histamine
and TNFα increase permeability, whereas anti-inﬂammatory mediators
including sphingosine 1-phosphate (S1P) and angiopoietin-1 decrease
permeability [23]. Increased vascular barrier leakage is associated with
Fig. 1. The main transmembrane proteins in endothelial cell-cell junctions. Endothelial cells line the blood stream and are constantly exposed to ﬂuid shear stress (top
panel). The bottom panel shows the main transmembrane proteins in endothelial cell-cell junctions (right). They are associated with tight junctions or adherens junctions as indicated,
with the exception of PECAM-1, which is not associated with either type of junction. Three diﬀerent claudin, JAM and nectin genes are reported to be expressed in endothelial cells
(numbers/letters indicated under protein name). Intracellular proteins link transmembrane proteins to the actin cytoskeleton. There are additional junctional molecules, such as CD99
and ESAM, which are omitted for clarity.
Fig. 2. Signaling molecules that regulate vascular permeability. The main junctional proteins that regulate vascular permeability are shown on the right cell. The left cell shows
examples of receptors that increase vascular permeability, and the intracellular signaling molecules that contribute to this response, focusing on those regulated by Rho and Rap
GTPases. ROS, reactive oxygen species.
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disruption of endothelial junctions, in particular AJs [10], and occurs
in diseases such as cancer, atherosclerosis, diabetes, hypertension,
inﬂammation, and ischemia [24,25]. In addition, cerebral cavernous
malformations (CCMs) are inherited or sporadic diseases that are
associated with disorganization of venous brain microvessel junctions
and increased permeability [26].
3.1. Signals that increase endothelial permeability
Pro-inﬂammatory stimuli increase permeability through a combi-
nation of changes to AJ, TJ and the associated actin cytoskeleton
(Fig. 2). AJ composition and integrity is regulated by changes in
phosphorylation of junctional proteins. For example, thrombin acti-
vates the serine/threonine kinase protein kinase C (PKC)α, which
induces VE-cadherin complex disassembly by phosphorylating p120ctn
[27]. In VEGF-stimulated ECs, Src mediates Rac1 activation, leading to
VE-cadherin phosphorylation via the serine/threonine kinase PAK, and
thereby increasing endothelial permeability [28]. LPS activates the Rab
family GTPase Rab5, which mediates VE-cadherin internalization
resulting in increased permeability [29].
Tyrosine phosphorylation of AJ components is also associated with
increased permeability. In unstimulated ECs, receptor and cytoplasmic
protein tyrosine phosphatases (PTPs) localize to endothelial AJs and
de-phosphorylate AJ components to reduce permeability [17,30,31].
For example, the tyrosine phosphatase SHP2 associates with β-catenin
in VE-cadherin/p120/plakoglobin complexes [32]. Depletion of SHP2
enhances phosphorylation of AJ complex components leading to
increased permeability in response to thrombin [32,33]. TNFα in-
creases tyrosine phosphorylation of VE-cadherin to enhance vascular
permeability [34,35]. VE-cadherin Tyr685 phosphorylation is required
for VEGF- and histamine-induced permeability in vivo [36].
Furthermore, phosphorylation of VE-cadherin on Tyr658 and Tyr685
was reported to be required for increased permeability and endocytosis
of VE-cadherin in response to bradykinin and histamine [37].
Endothelial cell-cell contacts are linked to the actin cytoskeleton,
which is central to junction stability and contributes to changes in
vascular permeability [38]. Permeability-inducing factors destabilize
cell-cell junctions by changing actin bundle orientation, which switch
from being parallel to junctions to being perpendicular. Perpendicular
actin ﬁlaments, including stress ﬁbers, impose mechanical force on
junctions, and disrupt their integrity [39–41]. RhoA induces stress
ﬁbers and increases contractility leading to higher vascular perme-
ability in response to a variety of extracellular stimuli including
thrombin and histamine (Fig. 2). RhoA activates the serine/threonine
kinase ROCK, which phosphorylates the MYPT1 subunit of the trimeric
myosin light chain (MLC) phosphatase, thereby inhibiting its enzy-
matic activity [42,43]. Subsequent increased MLC phosphorylation
leads to increased actomyosin contractility. RhoA is required for
Fig. 3. Signaling molecules that regulate leukocyte transendothelial migration. Leukocyte attachment to and transmigration across endothelial cells is a multistep process,
involving a variety of diﬀerent adhesion molecules on leukocytes and endothelial cells (top panel). During transendothelial migration, endothelial adhesion molecules ICAM-1, VCAM-1
and PECAM-1 interact with leukocytes and transmit signals into the endothelial cell (bottom panel), which promote the transmigration process. The left cell shows signals involving
RhoG, Rac1 and Rap1 GTPases; the right cell shows signals involving RhoA. LBRC, lateral border recycling compartment; ROS, reactive oxygen species.
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increased permeability in response to several stimuli including throm-
bin and TNFα [44]. Interestingly, RhoB and RhoC are also activated by
thrombin [45], and RhoB promotes sustained thrombin-induced con-
traction [46]. By contrast, RhoA activation by angiopoietin-1 leads to
cell-cell junction stabilization and inhibits VEGF-induced permeability,
and this response is dependent on the Rho-activated formin mDia1 but
not ROCK [47]. This suggests that the eﬀect of RhoA on junctions
depends on whether it activates ROCK, promoting actomyosin con-
tractility, or on mDia1, which stimulates actin polymerization [48].
Increased permeability often reﬂects loss of TJ proteins from
junctions, which is linked to enhanced RhoA/ROCK signaling. For
example, ROCK induces phosphorylation of claudin-5 and occludin
[49]. TNFα increases permeability by inducing a decrease in claudin-5
at junctions via ROCK1 and ROCK2 [50]. LPS induces loss of TJ
proteins and increased endothelial permeability via activation of RhoA
by p115RhoGEF [51]. In the TJ complex, ZO-1 is bound to cingulin
which is linked to the actin cytoskeleton (Fig. 1). Cingulin promotes
endothelial barrier function in vitro and in vivo, in part by interacting
with and inhibiting the RhoA GEF-H1 [52,53], whereas the cingulin-
like protein JACOP associates with p114RhoGEF to maintain endothe-
lial TJs and AJs, presumably by stimulating RhoA activity at cell-cell
junctions [15]. This indicates that the site of RhoA activation, and
which of its targets it stimulates, determines whether it inhibits or
stimulates junction disruption.
3.2. Signals that reduce permeability
Stimuli that reduce permeability and promote endothelial barrier
function generally act through three small GTPases, Rap1, Rac1 and
Cdc42, and as described above in some cases RhoA, which act together
through inter-connected signaling networks (Fig. 2). For example,
thrombin initially increases endothelial permeability through RhoA,
but also increases S1P generation, which then stimulates Rac1 activa-
tion resulting in enhanced barrier integrity to reverse the thrombin-
induced permeability [54].
Endothelial junctional integrity is enhanced by stimuli that elevate
cAMP levels, such as adrenomedullin, prostacyclin, prostaglandin E2,
and β-adrenergic agonists, which reduce EC permeability [55]. cAMP
directly activates the RapGEF Epac, which activates Rap1 [56]. There
are two Rap1 proteins, Rap1a and Rap1b. Rap1b is most highly
expressed in ECs, but Rap1a depletion reduces EC barrier function
more than Rap1b depletion, which could be explained by its colocaliza-
tion with VE-cadherin at AJs [57].
Rap1 acts through multiple pathways to promote VE-cadherin-
mediated adhesion and maintain barrier function [56]. First, it leads to
activation of Rac1 and Cdc42, which in turn strengthen endothelial
cell-cell junctions. For example, Epac1/Rap1 act via the Rac GEFs
Tiam1 and Vav2 to promote Rac1 activation [55]. In addition,
circulating erythrocytes or platelets release S1P that activates Rac1
downstream of Rap1 via Akt, leading to endothelial barrier stabiliza-
tion [58,59]. Rap1 also promotes the assembly of a junctional
mechanosensing complex of PECAM1, VE-cadherin and VEGFR2 in
response to shear stress, which then activates Rac1 via Vav2 and Tiam1
to increase barrier function [60–62]. Finally, Rap1 activates Cdc42 via
the RhoGEF FGD5 to promote cell-cell junction stabilization [63,64].
In addition to activating Rac1 and Cdc42, Rap1 acts via several
mechanisms to reduce RhoA/ROCK activity resulting in increased
endothelial barrier function (Fig. 2). It acts via its eﬀector Rasip1,
which recruits the RhoGAP ARHGAP29 to inhibit RhoA and ROCK
activity [65,66]. Rasip1 also decreases stress ﬁber formation and
endothelial permeability by direct interaction with the transmembrane
receptor heart of glass (HEG1) [67]. Furthermore, Rap1 controls the
endothelial barrier by recruiting its eﬀector CCM1/KRIT1 to EC
junctions, which reduces stress ﬁbers and RhoA activity in ECs
[68,69]. In contrast to Rap1, Rap2 depletion increases endothelial
barrier resistance, although the mechanism whereby Rap2 alters
barrier function is not known [70].
Rac1 increases EC junction stability and hence reduces perme-
ability, both by stimulating extension of lamellipodia to close inter-
cellular gaps and by inducing assembly of cortical F-actin bundles and
reducing actomyosin tension [71,72]. In addition, shear stress acts via
VE-cadherin, Tiam1 and Rac1 to reduce the level of tyrosine phos-
phorylation on occludin, leading to barrier enhancement [73], although
the tyrosine phosphatase involved in this pathway has not been
identiﬁed, Angiopoietin-1 reduces occludin tyrosine phosphorylation
via the protein tyrosine phosphatase N-2 and promotes occludin
interaction with ZO-1 to enhance TJs [74], and thus it will be
interesting to test if this phosphatase acts downstream of Rac1.
Rac1 acts through several downstream eﬀectors to mediate junction
stabilization, including IQGAP1, which binds to Rac1 and Cdc42, and
interacts with activators of actin polymerization (N-WASP, Arp2/3
complex) to promote AJ assembly [75,76]. By contrast, Rac1 has been
reported to increase permeability downstream of VEGF via PAK-
mediated phosphorylation of a highly conserved motif within the
intracellular tail of VE-cadherin, Ser665, resulting in VE-cadherin
internalization [47]. VEGF activates VEGFR2 which associates with
VE-cadherin and activates Rac1 via Src and the RacGEF Vav2 [47].
VEGF can also act via the phosphatidylinositol (3,4,5)-trisphosphate-
dependent Rac exchanger 1 (P-Rex1) to activate Rac1 and increase
permeability [77]. It is therefore likely that the eﬀect of Rac1 on
permeability depends on the cellular context.
As well as being activated downstream of Rap1, Rac1 is locally
activated at cell-cell junctions, in part via the RhoGEFs Trio and Tiam1,
which interact with VE-cadherin [44,78–80]. On the other hand,
inﬂammatory mediators such as LPS, TNFα, angiotensin 2 and
thrombin reduce Rac1 activity resulting in junction opening and
increased permeability [81]. RhoB inhibits Rac1 activity at junctions
by reducing traﬃcking of Rac1 to cell-cell junctions. RhoB expression is
induced by the inﬂammatory cytokines TNFα and IL-1β, and promotes
sustained EC contraction upon thrombin exposure in the context of
inﬂammation [46].
Like Rac1, Cdc42 is important for maintaining AJs [82–84]. For
example, Cdc42 restores endothelial barrier function upon thrombin
stimulation [85]. Increased endothelial permeability induced by loss or
destabilization of VE-cadherin increases Cdc42 activity [84,86], which
presumably promotes junctional restoration. In vivo, Cdc42 is required
for endothelial cell-cell adhesion during development, and is necessary
for endothelial polarity [87].
Cdc42 acts via several mechanisms to stimulate AJ assembly. It
promotes the post-Golgi transport of VE-cadherin to AJs [88]and
controls α-catenin binding with β-catenin and interaction of the VE-
cadherin complex with the actin cytoskeleton [84]. In addition, Cdc42
controls actin organization thought two pathways: ﬁrst via its eﬀectors
PAK2 and PAK4 that regulate junctional actomyosin, and second via N-
WASP that is required for junctional actin assembly [87]. Cdc42 has
also been reported to act through the atypical protein kinase C PKCι to
mediate endothelial cell-cell adhesion in vivo [89].
Overall, endothelial permeability reﬂects the combined actions of
multiple signaling molecules, including small GTPases, kinases and
phosphatases, which directly modify junctional molecules as well as act
on the associated actin cytoskeleton to alter junctional integrity
(Fig. 2).
4. Signaling in endothelial junctions and leukocyte
transendothelial migration
Leukocyte TEM is essential both in immunosurveillance and during
tissue damage or infection [90,91]. TEM is a unique process in which a
leukocyte squeezes itself through the endothelium, and involves
dynamic signaling between leukocytes and ECs leading to the changes
in morphology required for TEM (Fig. 3).
Leukocytes cross the endothelium via a multistep cascade involving
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leukocyte capture, rolling, adhesion, and crawling on ECs followed by
leukocyte migration across the endothelium in the presence of shear
forces exerted by blood ﬂow (Fig. 3) [92–94]. Leukocytes can cross the
endothelium through two diﬀerent routes: paracellular, through the
cell-cell junctions, or transcellular, throught the endothelial cell body
[95,96]. The choice of route depends on the transmigrating cell type,
the site of TEM and the type of vascular endothelium [97,98].
Furthermore, the route of diapedesis depends on endothelial junctional
integrity: T-cells are more likely to take a transcellular route when
junctions are strengthened [99].
Several adhesion molecules expressed by ECs contribute to TEM,
including ICAM-1 and/or VCAM-1 on the luminal surface and PECAM-
1 and/or JAMs on the basolateral membranes [8,93,100]. The expres-
sion and regulation of these molecules depends on the shear stress of
the blood ﬂow, proinﬂammatory cytokines and chemokines, the
vascular bed and the stiﬀness of the tissue [101,102].
4.1. Leukocyte crawling and endothelial extension of docking
structures
Leukocytes initially crawl on ECs before arresting and transmigrat-
ing. The leukocyte integrin LFA-1/αLβ2 interaction with ICAM-1
activates RhoA [94]. RhoA promotes stiﬀening of the endothelial
surface, enhancing leukocyte migration over it and hence the ability
of leukocytes to ﬁnd a site for TEM. ICAM-1 activates RhoA through
the RhoGEF LARG (Leukemia-assiciated Rho GEF, ARHGEF12), and
depletion of endothelial LARG reduces leukocyte crawling on ECs
[103].
ECs often extend dynamic microvillus-like protrusions known as
docking structures or transmigratory cups around adherent leukocytes
(Fig. 3) [94]. These structures contribute to TEM, probably by
increasing leukocyte-endothelium contact area with minimal barrier
disruption and to help leukocytes extend protrusions to cross the
endothelium [104]. Initially ICAM-1 and VCAM-1 cluster in ring-like
structures around the leukocyte, followed by apical membrane protru-
sion. Anchorage of ICAM-1 to the actin cytoskeleton via adaptor
proteins, such as ﬁlamin and cortactin, is essential for formation of
ICAM-1 rings and subsequent leukocyte TEM [105–107].
Rac1 is required for ICAM-1 clustering, while RhoG controls
membrane protrusion (Fig. 3). RhoG is activated by ICAM-1 binding
to the RhoG-speciﬁc GEF SGEF [108]. ICAM-1 also associates with and
activates the GEF Trio, which activates Rac1 and then RhoG via its two
diﬀerent RhoGEF domains [109]. Interestingly, Trio expression is
strongly upregulated by TNFα stimulation, suggesting docking struc-
ture assembly is coupled to induction of ICAM-1 and VCAM-1 [109].
4.2. Crossing the endothelium and closing the transmigration pore
For paracellular TEM, two signaling events occur once the leuko-
cyte is anchored to the endothelium: local VE-cadherin internalization
via clathrin-coated vesicles and inﬂux of membrane and membrane
proteins including PECAM-1 from a lateral border recycling compart-
ment (LBRC) to the TEM site [110–113].
Junction opening involves VCAM-1 signaling to VE-cadherin.
VCAM-1 interaction with the leukocyte integrin VLA-4 induces Rac1
activation and subsequent production of intracellular reactive oxygen
species (ROS) by NADPH oxidase [114]. This in turn activates the
proline-rich tyrosine kinase (Pyk2) [115] which then phosphorylates
VE-cadherin on Tyr658 and Tyr731 resulting in local loss of VE-
cadherin function, junction opening and increased TEM (Fig. 3)
[36,116–118]. Inhibition of this pathway, through the PI3-kinase
p110α, Pyk2 and Rac1, reduces TEM [114,118–120]. Rac1, ROS and
Pyk2 also induce VE-PTP dissociation from VE-cadherin, leading to
increased tyrosine phosphorylation of VE-cadherin and VE-cadherin
internalization thereby facilitating transmigration [3,31,113,121].
Furthermore, endothelial signaling stimulates junctional actomyosin
contractility and acts on cell-cell junctional proteins, leading to
localised and transient junctional disassembly essential for leukocyte
TEM [94,122].
Multiple proteins are associated with the LBRC fraction during
TEM including PECAM-1, which is important for TEM [123,124].
PECAM-1 homotypic interaction starts the recruitment of the LBRC to
the site of leukocyte interaction. This is linked to localised recruitment
of the Ca2+ channel TRPC6, which increases intracellular Ca2+ and is
required for the ﬁnal stage of TEM, similar to PECAM-1 [125].
Increased intracellular Ca2+ triggers actomyosin contractility by myo-
sin light chain kinase (MLCK), which is required for TEM [102].
PECAM-1 is also involved in transcellular TEM, since ICAM-1 cluster-
ing on ECs is not suﬃcient to promote the transcellular pathway if
PECAM-1 is blocked [126].
Endothelial RhoA is activated locally by ICAM-1 during TEM
throught recruitment of the RhoGEFs LARG and Ect2 [45,97]. RhoA
activity is highest during the ﬁnal stage of extravasation, and mediates
endothelial F-actin remodelling to form ring structures around trans-
migrating leukocytes, which both prevent vascular leakage during
leukocyte diapedesis and promote pore closure and transmigration
[97].
5. Conclusions and future perspectives
Endothelial permeability and leukocyte TEM involve similar in-
tracellular signaling mechanisms, including Rho and Rap GTPase
signaling, cell-cell junction and F-actin remodelling, and thus it has
been diﬃcult to separate the two processes mechanistically. However, a
key diﬀerence between them is when and where the signals occur in
ECs. For leukocyte TEM, receptors are activated locally in ECs beneath
and around the leukocyte [94], whereas for endothelial permeability
the receptors are generally activated across the whole EC plasma
membrane and/or cell-cell junctions [4]. In addition, TEM does not
involve an increase in vascular permeability, rather that mechanisms
are in place to ensure minimal leakage [36,97,127]. Moreover, stimuli
leading to vascular permeability generally act within minutes [23],
whereas leukocyte TEM during inﬂammation requires upregulation of
leukocyte-binding receptors on ECs [91].
Although several signaling mechanisms are similar between en-
dothelial permeability and TEM, there are also signals that diﬀer,
which could be manipulated to inhibit one or the other process. For
example, diﬀerences in VE-cadherin tyrosine phosphorylation between
the two processes have been reported [36,128]. Future research should
identify how these phosphorylation sites mediate local versus global
changes to junctions in ECs. In addition, RhoG is so far only implicated
in TEM [108]. On the other hand, Rap1, RhoA and Rac1 are involved in
both processes. It is likely, however, that they are part of diﬀerent
protein complexes because the transmembrane receptors involved in
permeability and TEM are diﬀerent. Although several GEFs have been
identiﬁed to contribute to permeability and TEM, future research
should aim to identify which downstream targets and GAPs of Rho
and Rap GTPases are critical to vascular permeability versus leukocyte
TEM.
In contrast to leukocyte TEM, comparatively little is known about
the contribution of EC signaling to cancer TEM. Multiple receptors on
ECs have been implicated in mediating cancer cell TEM, but little is
known of their mechanistic roles beyond simply facilitating adhesion
[129]. Recently, Ephrin-1 was identiﬁed as a ligand on ECs that
stimulates tyrosine phosphorylation of EphA2 on cancer cells, inducing
cell-cell repulsion and leading to decreased TEM of breast cancer cells
[130]. It will be interesting to determine how other receptors con-
tribute to dynamic signaling between cancer cells and ECs.
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In conclusion, changes to vascular permeability and leukocyte TEM
are orchestrated by a combination of small GTPases, protein kinases
and phosphatases, which coordinate changes to endothelial cell-cell
junctions with the actin cytoskeleton. Targeting these signaling mole-
cules could be used to reduce inﬂammation and auto-immune diseases.
Acknowledgement
Organisations supporting research: Cancer Research UK grant no.
C6620/A15961
References
[1] B. Engelhardt, H. Wolburg, Mini-review: transendothelial migration of leuko-
cytes: through the front door or around the side of the house?, Eur. J. Immunol.
34 (2004) 2955–2963.
[2] H. Wolburg, A. Lippoldt, Tight junctions of the blood–brain barrier: development,
composition and regulation, Vasc. Pharmacol. 38 (2002) 323–337.
[3] D. Goswami, D. Vestweber, How leukocytes trigger opening and sealing of gaps in
the endothelial barrier, F1000Res (2016) 5.
[4] L. Claesson-Welsh, Vascular permeability – the essentials, Ups. J. Med. Sci. 120
(2015) 135–143.
[5] M.S. Balda, K. Matter, Tight junctions as regulators of tissue remodelling, Curr.
Opin. Cell Biol. 42 (2016) 94–101.
[6] M.Y. Radeva, J. Waschke, Mind the gap: mechanisms regulating the endothelial
barrier, Acta Physiol. (2017).
[7] R.F. Haseloﬀ, S. Dithmer, L. Winkler, H. Wolburg, I.E. Blasig, Transmembrane
proteins of the tight junctions at the blood-brain barrier: structural and functional
aspects, Semin. Cell Dev. Biol. 38 (2015) 16–25.
[8] N. Reglero-Real, B. Colom, J.V. Bodkin, S. Nourshargh, Endothelial cell junctional
adhesion molecules: role and regulation of expression in inﬂammation,
Arterioscler. Thromb. Vasc. Biol. 36 (2016) 2048–2057.
[9] A.C. Luissint, A. Nusrat, C.A. Parkos, JAM-related proteins in mucosal home-
ostasis and inﬂammation, Semin. Immunopathol. 36 (2014) 211–226.
[10] E. Dejana, D. Vestweber, The role of VE-cadherin in vascular morphogenesis and
permeability control, Prog. Mol. Biol. Transl. Sci. 116 (2013) 119–144.
[11] E. Dejana, F. Orsenigo, C. Molendini, P. Baluk, D.M. McDonald, Organization and
signaling of endothelial cell-to-cell junctions in various regions of the blood and
lymphatic vascular trees, Cell Tissue Res. 335 (2009) 17–25.
[12] P. Lertkiatmongkol, D. Liao, H. Mei, Y. Hu, P.J. Newman, Endothelial functions of
platelet/endothelial cell adhesion molecule-1 (CD31), Curr. Opin. Hematol. 23
(2016) 253–259.
[13] E. Dejana, C. Giampietro, Vascular endothelial-cadherin and vascular stability,
Curr. Opin. Hematol. 19 (2012) 218–223.
[14] A. Taddei, C. Giampietro, A. Conti, F. Orsenigo, F. Breviario, V. Pirazzoli,
M. Potente, C. Daly, S. Dimmeler, E. Dejana, Endothelial adherens junctions
control tight junctions by VE-cadherin-mediated upregulation of claudin-5, Nat.
Cell Biol. 10 (2008) 923–934.
[15] O. Tornavaca, M. Chia, N. Dufton, L.O. Almagro, D.E. Conway, A.M. Randi,
M.A. Schwartz, K. Matter, M.S. Balda, ZO-1 controls endothelial adherens
junctions, cell-cell tension, angiogenesis, and barrier formation, J. Cell Biol. 208
(2015) 821–838.
[16] K. Ebnet, Organization of multiprotein complexes at cell-cell junctions,
Histochem. Cell Biol. 130 (2008) 1–20.
[17] D. Vestweber, VE-cadherin: the major endothelial adhesion molecule controlling
cellular junctions and blood vessel formation, Arterioscler. Thromb. Vasc. Biol. 28
(2008) 223–232.
[18] M. Wang, P.J. Casey, Protein prenylation: unique fats make their mark on biology,
Nat. Rev. Mol. Cell Biol. 17 (2016) 110–122.
[19] R.G. Hodge, A.J. Ridley, Regulating Rho GTPases and their regulators, Nat. Rev.
Mol. Cell Biol. 17 (2016) 496–510.
[20] H. Xiao, X. Qin, D. Ping, K. Zuo, Inhibition of Rho and Rac geranylgeranylation by
atorvastatin is critical for preservation of endothelial junction integrity, PLoS One
8 (2013) e59233.
[21] R. Garcia-Mata, E. Boulter, K. Burridge, The 'invisible hand': regulation of RHO
GTPases by RHOGDIs, Nat. Rev. Mol. Cell Biol. 12 (2011) 493–504.
[22] P. Riou, S. Kjaer, R. Garg, A. Purkiss, R. George, R.J. Cain, G. Bineva,
N. Reymond, B. McColl, A.J. Thompson, et al., 14-3-3 proteins interact with a
hybrid prenyl-phosphorylation motif to inhibit G proteins, Cell 153 (2013)
640–653.
[23] D. Mehta, A.B. Malik, Signaling mechanisms regulating endothelial permeability,
Physiol. Rev. 86 (2006) 279–367.
[24] E. Dejana, E. Tournier-Lasserve, B.M. Weinstein, The control of vascular integrity
by endothelial cell junctions: molecular basis and pathological implications, Dev.
Cell 16 (2009) 209–221.
[25] C. Park-Windhol, P.A. D'Amore, Disorders of vascular permeability, Annu. Rev.
Pathol. 11 (2016) 251–281.
[26] M.G. Lampugnani, M. Malinverno, E. Dejana, Endothelial cell disease: emerging
knowledge from cerebral cavernous malformations, Curr. Opin. Hematol. (2017).
[27] E. Vandenbroucke St Amant, M. Tauseef, S.M. Vogel, X.P. Gao, D. Mehta,
Y.A. Komarova, A.B. Malik, PKCα activation of p120-catenin serine 879 phospho-
switch disassembles VE-cadherin junctions and disrupts vascular integrity, Circ.
Res. 111 (2012) 739–749.
[28] J. Gavard, V. Patel, J.S. Gutkind, Angiopoietin-1 prevents VEGF-induced en-
dothelial permeability by sequestering Src through mDia, Dev. Cell 14 (2008)
25–36.
[29] J. Yang, W. Yao, G. Qian, Z. Wei, G. Wu, G. Wang, Rab5-mediated VE-cadherin
internalization regulates the barrier function of the lung microvascular endothe-
lium, Cell Mol. Life Sci. 72 (2015) 4849–4866.
[30] Y. Wallez, F. Cand, F. Cruzalegui, C. Wernstedt, S. Souchelnytskyi, I. Vilgrain,
P. Huber, Src kinase phosphorylates vascular endothelial-cadherin in response to
vascular endothelial growth factor: identiﬁcation of tyrosine 685 as the unique
target site, Oncogene 26 (2007) 1067–1077.
[31] V. Kuppers, M. Vockel, A.F. Nottebaum, D. Vestweber, Phosphatases and kinases
as regulators of the endothelial barrier function, Cell Tissue Res. 355 (2014)
577–586.
[32] I. Timmerman, M. Hoogenboezem, A.M. Bennett, D. Geerts, P.L. Hordijk,
J.D. van Buul, The tyrosine phosphatase SHP2 regulates recovery of endothelial
adherens junctions through control of beta-catenin phosphorylation, Mol. Biol.
Cell 23 (2012) 4212–4225.
[33] J.A. Ukropec, M.K. Hollinger, S.M. Salva, M.J. Woolkalis, SHP2 association with
VE-cadherin complexes in human endothelial cells is regulated by thrombin, J.
Biol. Chem. 275 (2000) 5983–5986.
[34] D.J. Angelini, S.W. Hyun, D.N. Grigoryev, P. Garg, P. Gong, I.S. Singh,
A. Passaniti, J.D. Hasday, S.E. Goldblum, TNF-alpha increases tyrosine phos-
phorylation of vascular endothelial cadherin and opens the paracellular pathway
through fyn activation in human lung endothelia, Am. J. Physiol. Lung Cell Mol.
Physiol. 291 (2006) L1232–L1245.
[35] F.E. Nwariaku, Z. Liu, X. Zhu, R.H. Turnage, G.A. Sarosi, L.S. Terada, Tyrosine
phosphorylation of vascular endothelial cadherin and the regulation of micro-
vascular permeability, Surgery 132 (2002) 180–185.
[36] F. Wessel, M. Winderlich, M. Holm, M. Frye, R. Rivera-Galdos, M. Vockel,
R. Linnepe, U. Ipe, A. Stadtmann, A. Zarbock, et al., Leukocyte extravasation and
vascular permeability are each controlled in vivo by diﬀerent tyrosine residues of
VE-cadherin, Nat. Immunol. 15 (2014) 223–230.
[37] F. Orsenigo, C. Giampietro, A. Ferrari, M. Corada, A. Galaup, S. Sigismund,
G. Ristagno, L. Maddaluno, G.Y. Koh, D. Franco, et al., Phosphorylation of VE-
cadherin is modulated by haemodynamic forces and contributes to the regulation
of vascular permeability in vivo, Nat. Commun. 3 (2012) 1208.
[38] J.D. van Buul, I. Timmerman, Small Rho GTPase-mediated actin dynamics at
endothelial adherens junctions, Small GTPases 7 (2016) 21–31.
[39] K. Noda, J. Zhang, S. Fukuhara, S. Kunimoto, M. Yoshimura, N. Mochizuki,
Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to
circumferential actin bundles through α- and β-catenins in cyclic AMP-Epac-Rap1
signal-activated endothelial cells, Mol. Biol. Cell 21 (2010) 584–596.
[40] J. Millan, R.J. Cain, N. Reglero-Real, C. Bigarella, B. Marcos-Ramiro,
L. Fernandez-Martin, I. Correas, A.J. Ridley, Adherens junctions connect stress
ﬁbres between adjacent endothelial cells, BMC Biol. 8 (2010) 11.
[41] M. Hirano, K. Hirano, Myosin di-phosphorylation and peripheral actin bundle
formation as initial events during endothelial barrier disruption, Sci. Rep. 6
(2016) 20989.
[42] H. Sun, J.W. Breslin, J. Zhu, S.Y. Yuan, M.H. Wu, Rho and ROCK signaling in
VEGF-induced microvascular endothelial hyperpermeability, Microcirculation 13
(2006) 237–247.
[43] G.P. van Nieuw Amerongen, C.M. Beckers, I.D. Achekar, S. Zeeman, R.J. Musters,
V.W. van Hinsbergh, Involvement of Rho kinase in endothelial barrier main-
tenance, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2332–2339.
[44] C.M. Beckers, V.W. van Hinsbergh, G.P. van Nieuw Amerongen, Driving Rho
GTPase activity in endothelial cells regulates barrier integrity, Thromb. Haemost.
103 (2010) 40–55.
[45] N.R. Reinhard, S.F. van Helden, E.C. Anthony, T. Yin, Y.I. Wu, J. Goedhart,
T.W. Gadella, P.L. Hordijk, Spatiotemporal analysis of RhoA/B/C activation in
primary human endothelial cells, Sci. Rep. 6 (2016) 25502.
[46] B. Marcos-Ramiro, D. Garcia-Weber, S. Barroso, J. Feito, M.C. Ortega,
E. Cernuda-Morollon, N. Reglero-Real, L. Fernandez-Martin, M.C. Duran,
M.A. Alonso, et al., RhoB controls endothelial barrier recovery by inhibiting Rac1
traﬃcking to the cell border, J. Cell Biol. 213 (2016) 385–402.
[47] J. Gavard, J.S. Gutkind, VEGF controls endothelial-cell permeability by promot-
ing the β-arrestin-dependent endocytosis of VE-cadherin, Nat. Cell Biol. 8 (2006)
1223–1234.
[48] S. Kuhn, M. Geyer, Formins as eﬀector proteins of Rho GTPases, Small GTPases 5
(2014) e29513.
[49] M. Yamamoto, S.H. Ramirez, S. Sato, T. Kiyota, R.L. Cerny, K. Kaibuchi,
Y. Persidsky, T. Ikezu, Phosphorylation of claudin-5 and occludin by rho kinase in
brain endothelial cells, Am. J. Pathol. 172 (2008) 521–533.
[50] P.R. Clark, R.K. Kim, J.S. Pober, M.S. Kluger, Tumor necrosis factor disrupts
claudin-5 endothelial tight junction barriers in two distinct NF-κB-dependent
phases, PLoS One 10 (2015) e0120075.
[51] D. Xiaolu, P. Jing, H. Fang, Y. Lifen, W. Liwen, Z. Ciliu, Y. Fei, Role of
p115RhoGEF in lipopolysaccharide-induced mouse brain microvascular en-
dothelial barrier dysfunction, Brain Res. 1387 (2011) 1–7.
[52] Y. Tian, G. Gawlak, X. Tian, A.S. Shah, N. Sarich, S. Citi, A.A. Birukova, Role of
Cingulin in Agonist-induced Vascular Endothelial Permeability, J. Biol. Chem.
291 (2016) 23681–23692.
[53] K. Schossleitner, S. Rauscher, M. Groger, H.P. Friedl, R. Finsterwalder,
A. Habertheuer, M. Sibilia, C. Brostjan, D. Fodinger, S. Citi, et al., Evidence that
cingulin regulates endothelial barrier function in vitro and in vivo, Arterioscler.
Thromb. Vasc. Biol. 36 (2016) 647–654.
C. Cerutti, A.J. Ridley Experimental Cell Research 358 (2017) 31–38
36
[54] S. Mahajan-Thakur, A. Bohm, G. Jedlitschky, K. Schror, B.H. Rauch, Sphingosine-
1-Phosphate and Its receptors: a mutual link between blood coagulation and
inﬂammation, Mediat. Inﬂamm. 2015 (2015) 831059.
[55] N. Schlegel, J. Waschke, cAMP with other signaling cues converges on Rac1 to
stabilize the endothelial barrier- a signaling pathway compromised in inﬂamma-
tion, Cell Tissue Res. 355 (2014) 587–596.
[56] O.L. Roberts, C. Dart, cAMP signalling in the vasculature: the role of Epac
(exchange protein directly activated by cAMP), Biochem Soc. Trans. 42 (2014)
89–97.
[57] E.S. Wittchen, A. Aghajanian, K. Burridge, Isoform-speciﬁc diﬀerences between
Rap1A and Rap1B GTPases in the formation of endothelial cell junctions, Small
GTPases 2 (2011) 65–76.
[58] P.A. Singleton, S. Chatchavalvanich, P. Fu, J. Xing, A.A. Birukova, J.A. Fortune,
A.M. Klibanov, J.G. Garcia, K.G. Birukov, Akt-mediated transactivation of the
S1P1 receptor in caveolin-enriched microdomains regulates endothelial barrier
enhancement by oxidized phospholipids, Circ. Res. 104 (2009) 978–986.
[59] F.R. Curry, R.H. Adamson, Tonic regulation of vascular permeability, Acta
Physiol. 207 (2013) 628–649.
[60] C. Givens, E. Tzima, Endothelial mechanosignaling: does one sensor ﬁt all?,
Antioxid. Redox Signal. 25 (2016) 373–388.
[61] S. Lakshmikanthan, X. Zheng, Y. Nishijima, M. Sobczak, A. Szabo, J. Vasquez-
Vivar, D.X. Zhang, M. Chrzanowska-Wodnicka, Rap1 promotes endothelial
mechanosensing complex formation, NO release and normal endothelial function,
EMBO Rep. 16 (2015) 628–637.
[62] Y. Liu, C. Collins, W.B. Kiosses, A.M. Murray, M. Joshi, T.R. Shepherd,
E.J. Fuentes, E. Tzima, A novel pathway spatiotemporally activates Rac1 and
redox signaling in response to ﬂuid shear stress, J. Cell Biol. 201 (2013) 863–873.
[63] Y. Kurogane, M. Miyata, Y. Kubo, Y. Nagamatsu, R.K. Kundu, A. Uemura,
T. Ishida, T. Quertermous, K. Hirata, Y. Rikitake, FGD5 mediates proangiogenic
action of vascular endothelial growth factor in human vascular endothelial cells,
Arterioscler. Thromb. Vasc. Biol. 32 (2012) 988–996.
[64] K. Ando, S. Fukuhara, T. Moriya, Y. Obara, N. Nakahata, N. Mochizuki, Rap1
potentiates endothelial cell junctions by spatially controlling myosin II activity
and actin organization, J. Cell Biol. 202 (2013) 901–916.
[65] C.W. Wilson, L.H. Parker, C.J. Hall, T. Smyczek, J. Mak, A. Crow, G. Posthuma,
A. De Maziere, M. Sagolla, C. Chalouni, et al., Rasip1 regulates vertebrate vascular
endothelial junction stability through Epac1-Rap1 signaling, Blood 122 (2013)
3678–3690.
[66] A. Post, W.J. Pannekoek, B. Ponsioen, M.J. Vliem, J.L. Bos, Rap1 Spatially
Controls ArhGAP29 To Inhibit Rho Signaling during Endothelial Barrier
Regulation, Mol. Cell Biol. 35 (2015) 2495–2502.
[67] B.J. de Kreuk, A.R. Gingras, J.D. Knight, J.J. Liu, A.C. Gingras, M.H. Ginsberg,
Heart of glass anchors Rasip1 at endothelial cell-cell junctions to support vascular
integrity, Elife 5 (2016) e11394.
[68] J.J. Liu, R.A. Stockton, A.R. Gingras, A.J. Ablooglu, J. Han, A.A. Bobkov,
M.H. Ginsberg, A mechanism of Rap1-induced stabilization of endothelial cell–
cell junctions, Mol. Biol. Cell 22 (2011) 2509–2519.
[69] R.A. Stockton, R. Shenkar, I.A. Awad, M.H. Ginsberg, Cerebral cavernous
malformations proteins inhibit Rho kinase to stabilize vascular integrity, J. Exp.
Med. 207 (2010) 881–896.
[70] W.J. Pannekoek, J.R. Linnemann, P.M. Brouwer, J.L. Bos, H. Rehmann, Rap1 and
Rap2 antagonistically control endothelial barrier resistance, PLoS One 8 (2013)
e57903.
[71] J.W. Breslin, X.E. Zhang, R.A. Worthylake, F.M. Souza-Smith, Involvement of
local lamellipodia in endothelial barrier function, PLoS One 10 (2015) e0117970.
[72] N. Daneshjou, N. Sieracki, G.P. van Nieuw Amerongen, D.E. Conway,
M.A. Schwartz, Y.A. Komarova, A.B. Malik, Rac1 functions as a reversible tension
modulator to stabilize VE-cadherin trans-interaction, J. Cell Biol. 208 (2015)
23–32.
[73] T.G. Walsh, R.P. Murphy, P. Fitzpatrick, K.D. Rochfort, A.F. Guinan, A. Murphy,
P.M. Cummins, Stabilization of brain microvascular endothelial barrier function
by shear stress involves VE-cadherin signaling leading to modulation of pTyr-
occludin levels, J. Cell Physiol. 226 (2011) 3053–3063.
[74] M.R. Siddiqui, C.S. Mayanil, K.S. Kim, T. Tomita, Angiopoietin-1 regulates brain
endothelial permeability through PTPN-2 mediated tyrosine dephosphorylation of
occludin, PLoS One 10 (2015) e0130857.
[75] M.D. Brown, D.B. Sacks, IQGAP1 in cellular signaling: bridging the GAP, Trends
Cell Biol. 16 (2006) 242–249.
[76] Y. Tian, X. Tian, G. Gawlak, N. Sarich, D.B. Sacks, A.A. Birukova, K.G. Birukov,
Role of IQGAP1 in endothelial barrier enhancement caused by OxPAPC, Am. J.
Physiol. Lung Cell Mol. Physiol. 00095 (2016) 02016 (ajplung.00095.02016).
[77] R.P. Naikawadi, N. Cheng, S.M. Vogel, F. Qian, D. Wu, A.B. Malik, R.D. Ye, A
critical role for phosphatidylinositol (3,4,5)-trisphosphate-dependent Rac ex-
changer 1 in endothelial junction disruption and vascular hyperpermeability, Circ.
Res. 111 (2012) 1517–1527.
[78] Y. Baumer, V. Spindler, R.C. Werthmann, M. Bunemann, J. Waschke, Role of Rac
1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier
breakdown, J. Cell Physiol. 220 (2009) 716–726.
[79] I. Timmerman, N. Heemskerk, J. Kroon, A. Schaefer, J. van Rijssel,
M. Hoogenboezem, J. van Unen, J. Goedhart, T.W. Gadella Jr., T. Yin, et al., A
local VE-cadherin and trio-based signaling complex stabilizes endothelial junc-
tions through Rac1, J. Cell Sci. 128 (2015) 3041–3054.
[80] P. Boissier, U. Huynh-Do, The guanine nucleotide exchange factor Tiam1: a
Janus-faced molecule in cellular signaling, Cell Signal 26 (2014) 483–491.
[81] X.E. Zhang, S.P. Adderley, J.W. Breslin, Activation of RhoA, but Not Rac1,
Mediates Early Stages of S1P-Induced Endothelial Barrier Enhancement, PLoS
One 11 (2016) e0155490.
[82] M.J. Phillips, G. Calero, B. Chan, S. Ramachandran, R.A. Cerione, Eﬀector
proteins exert an important inﬂuence on the signaling-active state of the small
GTPase Cdc42, J. Biol. Chem. 283 (2008) 14153–14164.
[83] K.G. Birukov, V.N. Bochkov, A.A. Birukova, K. Kawkitinarong, A. Rios, A. Leitner,
A.D. Verin, G.M. Bokoch, N. Leitinger, J.G. Garcia, Epoxycyclopentenone-
containing oxidized phospholipids restore endothelial barrier function via Cdc42
and Rac, Circ. Res. 95 (2004) 892–901.
[84] M.T. Broman, P. Kouklis, X. Gao, R. Ramchandran, R.F. Neamu, R.D. Minshall,
A.B. Malik, Cdc42 regulates adherens junction stability and endothelial perme-
ability by inducing α-catenin interaction with the vascular endothelial cadherin
complex, Circ. Res. 98 (2006) 73–80.
[85] P. Kouklis, M. Konstantoulaki, S. Vogel, M. Broman, A.B. Malik, Cdc42 regulates
the restoration of endothelial barrier function, Circ. Res. 94 (2004) 159–166.
[86] P. Kouklis, M. Konstantoulaki, A.B. Malik, VE-cadherin-induced Cdc42 signaling
regulates formation of membrane protrusions in endothelial cells, J. Biol. Chem.
278 (2003) 16230–16236.
[87] D.M. Barry, K. Xu, S.M. Meadows, Y. Zheng, P.R. Norden, G.E. Davis, O. Cleaver,
Cdc42 is required for cytoskeletal support of endothelial cell adhesion during
blood vessel formation in mice, Development 142 (2015) 3058–3070.
[88] B. Wang, F.G. Wylie, R.D. Teasdale, J.L. Stow, Polarized traﬃcking of E-cadherin
is regulated by Rac1 and Cdc42 in Madin-Darby canine kidney cells, Am. J.
Physiol. Cell Physiol. 288 (2005) C1411–C1419.
[89] Y. Qi, J. Liu, X. Wu, C. Brakebusch, M. Leitges, Y. Han, S.A. Corbett, S.F. Lowry,
A.M. Graham, S. Li, Cdc42 controls vascular network assembly through protein
kinase Ciota during embryonic vasculogenesis, Arterioscler. Thromb. Vasc. Biol.
31 (2011) 1861–1870.
[90] C. Scheiermann, P.S. Frenette, A. Hidalgo, Regulation of leucocyte homeostasis in
the circulation, Cardiovasc. Res. 107 (2015) 340–351.
[91] S. Nourshargh, R. Alon, Leukocyte migration into inﬂamed tissues, Immunity 41
(2014) 694–707.
[92] K. Ley, C. Laudanna, M.I. Cybulsky, S. Nourshargh, Getting to the site of
inﬂammation: the leukocyte adhesion cascade updated, Nat. Rev. Immunol. 7
(2007) 678–689.
[93] S. Nourshargh, P.L. Hordijk, M. Sixt, Breaching multiple barriers: leukocyte
motility through venular walls and the interstitium, Nat. Rev. Mol. Cell Biol. 11
(2010) 366–378.
[94] N. Heemskerk, J. van Rijssel, J.D. van Buul, Rho-GTPase signaling in leukocyte
extravasation: an endothelial point of view, Cell Adhes. Migr. 8 (2014) 67–75.
[95] W.A. Muller, Localized signals that regulate transendothelial migration, Curr.
Opin. Immunol. 38 (2016) 24–29.
[96] C.V. Carman, Mechanisms for transcellular diapedesis: probing and pathﬁnding
by 'invadosome-like protrusions', J. Cell Sci. 122 (2009) 3025–3035.
[97] N. Heemskerk, L. Schimmel, C. Oort, J. van Rijssel, T. Yin, B. Ma, J. van Unen,
B. Pitter, S. Huveneers, J. Goedhart, et al., F-actin-rich contractile endothelial
pores prevent vascular leakage during leukocyte diapedesis through local RhoA
signalling, Nat. Commun. 7 (2016) 10493.
[98] A. Woodﬁn, M.B. Voisin, M. Beyrau, B. Colom, D. Caille, F.M. Diapouli,
G.B. Nash, T. Chavakis, S.M. Albelda, G.E. Rainger, et al., The junctional adhesion
molecule JAM-C regulates polarized transendothelial migration of neutrophils in
vivo, Nat. Immunol. 12 (2011) 761–769.
[99] R. Martinelli, A.S. Zeiger, M. Whitﬁeld, T.E. Sciuto, A. Dvorak, K.J. Van Vliet,
J. Greenwood, C.V. Carman, Probing the biomechanical contribution of the
endothelium to lymphocyte migration: diapedesis by the path of least resistance,
J. Cell Sci. 127 (2014) 3720–3734.
[100] F.W. Luscinskas, S. Ma, A. Nusrat, C.A. Parkos, S.K. Shaw, Leukocyte transen-
dothelial migration: a junctional aﬀair, Semin. Immunol. 14 (2002) 105–113.
[101] A. Schaefer, P.L. Hordijk, Cell-stiﬀness-induced mechanosignaling – a key driver
of leukocyte transendothelial migration, J. Cell Sci. 128 (2015) 2221–2230.
[102] W.A. Muller, Transendothelial migration: unifying principles from the endothelial
perspective, Immunol. Rev. 273 (2016) 61–75.
[103] E.C. Lessey-Morillon, L.D. Osborne, E. Monaghan-Benson, C. Guilluy,
E.T. O'Brien, R. Superﬁne, K. Burridge, The RhoA guanine nucleotide exchange
factor, LARG, mediates ICAM-1-dependent mechanotransduction in endothelial
cells to stimulate transendothelial migration, J. Immunol. 192 (2014) 3390–3398.
[104] P.T. Sage, C.V. Carman, Settings and mechanisms for trans-cellular diapedesis,
Front. Biosci. (Landmark Ed.) 14 (2009) 5066–5083.
[105] E. Kanters, J. van Rijssel, P.J. Hensbergen, D. Hondius, F.P. Mul, A.M. Deelder,
A. Sonnenberg, J.D. van Buul, P.L. Hordijk, Filamin B mediates ICAM-1-driven
leukocyte transendothelial migration, J. Biol. Chem. 283 (2008) 31830–31839.
[106] M. Schnoor, F.P. Lai, A. Zarbock, R. Klaver, C. Polaschegg, D. Schulte, H.A. Weich,
J.M. Oelkers, K. Rottner, D. Vestweber, Cortactin deﬁciency is associated with
reduced neutrophil recruitment but increased vascular permeability in vivo, J.
Exp. Med. 208 (2011) 1721–1735.
[107] J. Van Rijssel, I. Timmerman, F.P. Van Alphen, M. Hoogenboezem,
O. Korchynskyi, D. Geerts, J. Geissler, K.A. Reedquist, H.W. Niessen, J.D. Van
Buul, The Rho-GEF Trio regulates a novel pro-inﬂammatory pathway through the
transcription factor Ets2, Biol. Open 2 (2013) 569–579.
[108] J.D. van Buul, M.J. Allingham, T. Samson, J. Meller, E. Boulter, R. Garcia-Mata,
K. Burridge, RhoG regulates endothelial apical cup assembly downstream from
ICAM1 engagement and is involved in leukocyte trans-endothelial migration, J.
Cell Biol. 178 (2007) 1279–1293.
[109] J. van Rijssel, J. Kroon, M. Hoogenboezem, F.P. van Alphen, R.J. de Jong,
E. Kostadinova, D. Geerts, P.L. Hordijk, J.D. van Buul, The Rho-guanine
nucleotide exchange factor Trio controls leukocyte transendothelial migration by
promoting docking structure formation, Mol. Biol. Cell 23 (2012) 2831–2844.
C. Cerutti, A.J. Ridley Experimental Cell Research 358 (2017) 31–38
37
[110] P. Alcaide, G. Newton, S. Auerbach, S. Sehrawat, T.N. Mayadas, D.E. Golan,
P. Yacono, P. Vincent, A. Kowalczyk, F.W. Luscinskas, p120-Catenin regulates
leukocyte transmigration through an eﬀect on VE-cadherin phosphorylation,
Blood 112 (2008) 2770–2779.
[111] S.K. Shaw, P.S. Bamba, B.N. Perkins, F.W. Luscinskas, Real-time imaging of
vascular endothelial-cadherin during leukocyte transmigration across endothe-
lium, J. Immunol. 167 (2001) 2323–2330.
[112] D. Schulte, V. Kuppers, N. Dartsch, A. Broermann, H. Li, A. Zarbock,
O. Kamenyeva, F. Kiefer, A. Khandoga, S. Massberg, et al., Stabilizing the VE-
cadherin-catenin complex blocks leukocyte extravasation and vascular perme-
ability, Embo J. 30 (2011) 4157–4170.
[113] M. Vockel, D. Vestweber, How T cells trigger the dissociation of the endothelial
receptor phosphatase VE-PTP from VE-cadherin, Blood 122 (2013) 2512–2522.
[114] J.M. Cook-Mills, J.D. Johnson, T.L. Deem, A. Ochi, L. Wang, Y. Zheng, Calcium
mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion
molecule-1) stimulation of NADPH oxidase activity, Biochem. J. 378 (2004)
539–547.
[115] R. Mishra, S.K. Singh, HIV-1 Tat C phosphorylates VE-cadherin complex and
increases human brain microvascular endothelial cell permeability, BMC
Neurosci. 15 (2014) 80.
[116] J.D. van Buul, E.C. Anthony, M. Fernandez-Borja, K. Burridge, P.L. Hordijk,
Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-
based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation, J.
Biol. Chem. 280 (2005) 21129–21136.
[117] M.J. Allingham, J.D. van Buul, K. Burridge, ICAM-1-mediated, Src- and Pyk2-
dependent vascular endothelial cadherin tyrosine phosphorylation is required for
leukocyte transendothelial migration, J. Immunol. 179 (2007) 4053–4064.
[118] R.J. Cain, B. Vanhaesebroeck, A.J. Ridley, The PI3K p110alpha isoform regulates
endothelial adherens junctions via Pyk2 and Rac1, J. Cell Biol. 188 (2010)
863–876.
[119] S. van Wetering, J.D. van Buul, S. Quik, F.P. Mul, E.C. Anthony, J.P. ten Klooster,
J.G. Collard, P.L. Hordijk, Reactive oxygen species mediate Rac-induced loss of
cell-cell adhesion in primary human endothelial cells, J. Cell Sci. 115 (2002)
1837–1846.
[120] S. van Wetering, N. van den Berk, J.D. van Buul, F.P. Mul, I. Lommerse, R. Mous,
J.P. ten Klooster, J.J. Zwaginga, P.L. Hordijk, VCAM-1-mediated Rac signaling
controls endothelial cell-cell contacts and leukocyte transmigration, Am. J.
Physiol. Cell Physiol. 285 (2003) C343–C352.
[121] A.F. Nottebaum, G. Cagna, M. Winderlich, A.C. Gamp, R. Linnepe, C. Polaschegg,
K. Filippova, R. Lyck, B. Engelhardt, O. Kamenyeva, et al., VE-PTP maintains the
endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by
leukocytes and by VEGF, J. Exp. Med. 205 (2008) 2929–2945.
[122] S. Barzilai, S.K. Yadav, S. Morrell, F. Roncato, E. Klein, L. Stoler-Barak, O. Golani,
S.W. Feigelson, A. Zemel, S. Nourshargh, et al., Leukocytes breach endothelial
barriers by insertion of nuclear lobes and disassembly of endothelial actin
ﬁlaments, Cell Rep. 18 (2017) 685–699.
[123] Z. Mamdouh, G.E. Kreitzer, W.A. Muller, Leukocyte transmigration requires
kinesin-mediated microtubule-dependent membrane traﬃcking from the lateral
border recycling compartment, J. Exp. Med. 205 (2008) 951–966.
[124] D.P. Sullivan, C. Ruﬀer, W.A. Muller, Isolation of the lateral border recycling
compartment using a diaminobenzidine-induced density shift, Traﬃc 15 (2014)
1016–1029.
[125] E.W. Weber, F. Han, M. Tauseef, L. Birnbaumer, D. Mehta, W.A. Muller, TRPC6 is
the endothelial calcium channel that regulates leukocyte transendothelial migra-
tion during the inﬂammatory response, J. Exp. Med. 212 (2015) 1883–1899.
[126] Z. Mamdouh, A. Mikhailov, W.A. Muller, Transcellular migration of leukocytes is
mediated by the endothelial lateral border recycling compartment, J. Exp. Med.
206 (2009) 2795–2808.
[127] R.C. Winger, J.E. Koblinski, T. Kanda, R.M. Ransohoﬀ, W.A. Muller, Rapid
remodeling of tight junctions during paracellular diapedesis in a human model of
the blood-brain barrier, J. Immunol. 193 (2014) 2427–2437.
[128] A. Sidibe, B.A. Imhof, VE-cadherin phosphorylation decides: vascular perme-
ability or diapedesis, Nat. Immunol. 15 (2014) 215–217.
[129] N. Reymond, B.B. d'Agua, A.J. Ridley, Crossing the endothelial barrier during
metastasis, Nat. Rev. Cancer 13 (2013) 858–870.
[130] M. Locard-Paulet, L. Lim, G. Veluscek, K. McMahon, J. Sinclair, A. van
Weverwijk, J.D. Worboys, Y. Yuan, C.M. Isacke, C. Jorgensen, Phosphoproteomic
analysis of interacting tumor and endothelial cells identiﬁes regulatory mechan-
isms of transendothelial migration, Sci. Signal. 9 (2016) (ra15).
C. Cerutti, A.J. Ridley Experimental Cell Research 358 (2017) 31–38
38
